Bioharmony Therapeutics Inc. was founded in July 2016. We are a multidisciplinary team of microbiologists and infectious diseases specialists singularly focused on helping solve the antimicrobial resistance crisis by developing new, first-in-class drugs to treat bacterial infections, including those caused by multidrug-resistant pathogens. Backed by some of the leading scientific and business leaders, we feel we are up for this challenge.
Lysins are enzymes, isolated from bacteriophages, which are capable of cleaving bonds in the bacterial cell wall, resulting in the death of the bacteria within seconds after contact. Lysins are the result of millions of years of evolution of the bacteriophage for the efficient release of their progeny phage from a phage-infected bacterium. Through evolutionary selection, these lysins target a critical component in the cell wall, making resistance to them orders of magnitude less likely than for conventional antibiotics. Such properties make them uniquely suitable for the treatment of multidrug resistant (MDR) pathogens. Our initial product candidates are new agents to treat lethal, resistant infections such as those caused by resistant Gram-negative pathogens like MDR and carbapenem-resistant Acinetobacter baumannii, Pseudomonas aeruginosa and others listed on WHO’s Priority Pathogen List.
The Rockefeller University Licensing Agreement
Dr. Vince Fischetti joins Bioharmony’s Scientific Advisory Board
ANY Seed Funding
Boehringer Ingelheim Collaboration Initiated
Labs Established at LaunchLabs NY